Overview

Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-02-10
Target enrollment:
Participant gender:
Summary
The goal of this prospective clinical trial is to evaluate efficacy and safety of irinotecan liposomes for first-line treatment of advanced colorectal cancer. The primary endpoint is Objective response rate (ORR) per RECIST 1.1. The secondary endpoints are overall survival (OS), progression-free survival (PFS), disease control rate (DCR) and safety based on NCI-CTCAE 5.0
Phase:
PHASE2
Details
Lead Sponsor:
Fudan University